Financing - July 28, 2025
Gesynta Pharma raises SEK 347 million
The company has raised an additional SEK 43 million in its Series B second closing, bringing the total Series B capital to SEK 347 million.
Pharma Business - July 17, 2025
AlzeCure’s pain project granted orphan drug status in the US
The US Food and Drug Administration (FDA) has granted the company's application for orphan drug status for the clinical pain candidate drug ACD440.
Pharma Business - July 7, 2025
AstraZeneca’s Imfinzi approved in the EU
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) for the treatment of adult patients with resectable muscle-invasive bladder cancer (MIBC) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as monotherapy adjuvant treatment after radical cystectomy (surgery to remove the bladder).
New Market - July 2, 2025
Camurus’ Oczyesa receives marketing authorization in the EU
Camurus has announced that the European Commission (EC) has granted Oczyesa, octreotide subcutaneous depot, marketing authorization for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogs.
Collaboration - June 25, 2025
Oxcia enters a research collaboration with LEO Pharma
The two companies will explore OXC-101 in topical formulations for medical dermatology indications including psoriasis.
Pharma Business - June 24, 2025
Novo Nordisk’s Ozempic receives EU recommendation in peripheral arterial disease
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial. STRIDE is the only dedicated PAD functional outcomes trial with a glucagon-like peptide-1 receptor […]
